Open ReMEdi clinical trial, UK [Lindus Health, Alfred E. Tiefenbacher GmbH]

I got ChatGPT to do a deep search and it came back with this:

PHOE 01, the drug in the ReMEdi ME/CFS trial, might actually be amifampridine.

A few hints:
  • The sponsor, Tiefenbacher, just launched amifampridine 10 mg tablets in Europe.
  • Trial info mentions it’s a drug with “proven success in other fatigue-related conditions,” which fits amifampridine’s use in Lambert-Eaton syndrome.
  • Screening questions about heart arrhythmias and QT interval line up with the known cardiac risks of potassium-channel blockers - and specifically amifampridine has these known cardiac risks.
Nothing is officially confirmed yet, but the clues point strongly in that direction.
 
I got ChatGPT to do a deep search and it came back with this:

PHOE 01, the drug in the ReMEdi ME/CFS trial, might actually be amifampridine.

A few hints:
  • The sponsor, Tiefenbacher, just launched amifampridine 10 mg tablets in Europe.
  • Trial info mentions it’s a drug with “proven success in other fatigue-related conditions,” which fits amifampridine’s use in Lambert-Eaton syndrome.
  • Screening questions about heart arrhythmias and QT interval line up with the known cardiac risks of potassium-channel blockers - and specifically amifampridine has these known cardiac risks.
Nothing is officially confirmed yet, but the clues point strongly in that direction.
That was mentioned by someone else as well, but without any sources:
 
Back
Top Bottom